Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 trial of Oravax's COVID-19 vaccine

Next Previous
X
Search
Trial Profile

Phase 2/3 trial of Oravax's COVID-19 vaccine

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 18 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccine-Oravax Medical (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Oramed Pharmaceuticals

    • Most Recent Events

    • 12 Jan 2022 According to an Oramed Pharmaceuticals media release, Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022.
    • 08 Nov 2021 New trial record
    • 29 Oct 2021 According to an Oramed Pharmaceuticals media release, the company expect to initiate this study for emergency use approval in relevant countries.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top